LADR™ Technology Platform
Our innovative LADR™ (Linker Activated Drug Release) technology employs a broad portfolio of novel linker molecules that selectively bind to circulating albumin and have the ability to be linked to a wide variety of anti-cancer payloads. Our research efforts currently center on creating new molecules from the combination of ultra-high potency cytotoxic payloads with tunable linkers. The molecules that we are currently evaluating concentrate at the tumor site providing targeted delivery of the chemotherapeutic payloads.
As a result of the determined efforts of our world-class scientists at our laboratory in Freiburg, Germany, we recently announced the nomination of DK049 as our next clinical candidate.